Monopar Therapeutics Inc
MNPR40.220USD
-0.470-1.16%
交易中 （美东）报价延迟15分钟
245.95M总市值
亏损市盈率 TTM
关于 Monopar Therapeutics Inc 公司
Monopar Therapeutics Inc. 是一家临床阶段的生物制药公司，专注于开发癌症患者的治疗方法。该公司正在通过内部开发以及授权和收购处于临床前和临床开发阶段的治疗药物来建立候选药物渠道。该公司正在开发几种化合物，包括 MNPR-101-Zr、MNPR-101-RIT、Camsirubicin 和 MNPR-202。MNPR-101-Zr 是一种临床阶段的尿激酶纤溶酶原激活剂受体 (uPAR) 靶向放射诊断显像剂。MNPR-101-RIT 是一种用于晚期癌症的临床前阶段放射治疗药物。Camsirubicin 是阿霉素的类似物，旨在减少阿霉素产生的心脏毒性副作用，同时保留有效的抗癌活性。 MNPR-202 是卡马西柔比星的早期类似物，旨在治疗对阿霉素和卡马西柔比星有耐药性的癌症。
公司简介
公司代码MNPR
公司名称Monopar Therapeutics Inc
上市日期Dec 19, 2019
CEODr. Chandler D. Robinson, M.D.
员工数量16
证券类型Ordinary Share
年结日Dec 19
公司地址1000 Skokie Blvd Ste 350
城市WILMETTE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编60091-1146
电话18473880349
网址https://www.monopartx.com/
公司代码MNPR
上市日期Dec 19, 2019
CEODr. Chandler D. Robinson, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月5日 周六
更新时间: 7月5日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
持股股东
持股股东
占比
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
股东类型
持股股东
占比
Corporation
29.77%
Investment Advisor/Hedge Fund
20.22%
Hedge Fund
16.45%
Venture Capital
8.36%
Individual Investor
4.79%
Investment Advisor
1.81%
Research Firm
0.55%
Pension Fund
0.15%
Other
17.91%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
75
5.02M
82.10%
-394.73K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
2023Q1
38
1.70M
67.19%
-3.29K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
1.13M
18.55%
+87.51K
+8.36%
Mar 31, 2025
Tactic Pharma LLC
822.25K
13.45%
-33.33K
-3.90%
Apr 04, 2025
Gem Pharmaceuticals LLC
611.08K
9.99%
--
--
Apr 04, 2025
Adage Capital Management, L.P.
599.20K
9.8%
--
--
Mar 31, 2025
RA Capital Management, LP
511.21K
8.36%
--
--
Mar 31, 2025
AstraZeneca PLC
387.33K
6.33%
+387.33K
--
Oct 23, 2024
Point72 Asset Management, L.P.
168.16K
2.75%
+268.00
+0.16%
Mar 31, 2025
Adar1 Capital Management LLC
100.77K
1.65%
-29.26K
-22.50%
Mar 31, 2025
Hendricks (Diane)
93.75K
1.53%
--
--
Apr 04, 2025
Robinson (Chandler D)
73.47K
1.2%
+7.48K
+11.33%
Jun 30, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
占比0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
公告日期
类型
比率
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
